Trial of Leptin Administration After Roux-en-Y Gastric Bypass

Overweight Clinical Trial

Official title:

Effects of Leptin on Body Weight and Neuroendocrine Axes After Gastric Bypass

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00710814
• Other study ID #: AAAC6692
• Secondary ID: R21DK081050UL1RR
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: July 1, 2008
• Last updated: October 16, 2015
• Start date: April 2008
• Est. completion date: July 2014

Study information

• Verified date: October 2015
• Source: Columbia University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

This is a pilot and feasibility study to examine a novel intervention using leptin in weight-reduced individuals who have undergone bariatric surgery but still remain obese. Leptin, a peptide hormone secreted from adipose tissue, is a regulator of food intake and energy expenditure. Administration of leptin resulted in profound weight reduction in the few reported cases of obese individuals with genetic leptin deficiency. However, most obese people have increased leptin levels. Such individuals are said to be in a "leptin-resistant" state, whereby administration of physiological concentrations of leptin are ineffective at producing significant weight reduction. Roux-en-Y gastric bypass surgery (RYGBP) is more effective than diet alone in producing long-term reduction of body weight. Yet even after surgery there is a plateau in weight loss though the individual may still be obese and have or be at risk for obesity related morbidities. The investigators have shown that plasma leptin levels are significantly lower in women after RYGBP compared with BMI-matched controls. This state of relative hypoleptinemia or leptin insufficiency suggests that post-RYGBP individuals may be in a "leptin-sensitive" state and, thus, would undergo further weight loss when administered doses of leptin that would not normally result in significant weight reduction. This study will examine the effects of leptin administered by self-injection twice per day on body weight and endocrine function. All individuals will received leptin and placebo and different times during the 34 week study period.

Description:

Metreleptin will be self-administered by subcutaneous injection at 0.05 mg/kg body weight twice per day (i.e. at 8 am and 8 pm). This dose was chosen because it would not be expected to cause substantial weight loss in an obese non-surgical population, nor should it incur any substantial injection site reactions. Subjects will receive a demonstration of dose preparation and injection in addition to written instructions with visual aides. After the run-in period, subjects will demonstrate their preparation and injection technique. Placebo injections will consist of sterile water equal in volume to that of the metreleptin dose calculated for each individual. Subjects will be instructed to continue with their current level of physical activity. At week 16, each subject will cross-over to the alternate treatment for an additional 16 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: July 2014
• Est. primary completion date: August 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 25 Years to 65 Years

Eligibility

Inclusion Criteria:

• Women ages 25-65 years who are 18 months to 15 years Roux-en-Y gastric bypass

• Current BMI of 28-50 kg/m2 and a percent total body weight loss from highest pre-surgical weight of >20% and <45%

• Must live in the vicinity of New York City to comply with 11 study visits over 34 weeks

• Must be willing to self-inject study drug twice per day

Exclusion Criteria:

• Diabetes

• History of plastic surgery

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Overweight

Intervention

Drug:
• Leptin
Leptin self-administered subcutaneously at 0.05 mg/kg body weight twice each day

Other:
• Placebo
Sterile water equal in volume to that of the metreleptin dose calculated for each individual self-administered subcutaneously twice each day

Locations

Country	Name	City	State
United States	Columbia University Medical Center	New York	New York

Sponsors (4)

Lead Sponsor	Collaborator
Columbia University	Amylin Pharmaceuticals, LLC., National Center for Research Resources (NCRR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Weight Change (in kg.) After Each Intervention	For the Leptin Intervention, 16 week values were compared to baseline for those who received Leptin in the first period, and 32 week values were compared to 16 week values in those who received Leptin in the second period.; For the Placebo Intervention, 16 week values were compared to baseline for those who received Placebo in the first period, and 32 week values were compared to 16 week values in those who received Placebo in the second period.	0 weeks, 16 weeks and 32 weeks	No